11-beta-Hydroxysteroid Dehydrogenase Type 2
"11-beta-Hydroxysteroid Dehydrogenase Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An high-affinity, NAD-dependent 11-beta-hydroxysteroid dehydrogenase that acts unidirectionally to catalyze the dehydrogenation of CORTISOL to CORTISONE. It is found predominantly in mineralocorticoid target tissues such as the KIDNEY; COLON; SWEAT GLANDS; and the PLACENTA. Absence of the enzyme leads to a fatal form of childhood hypertension termed, APPARENT MINERALOCORTICOID EXCESS SYNDROME.
| Descriptor ID |
D043209
|
| MeSH Number(s) |
D08.811.682.047.436.174.600 D08.811.682.047.820.100.600
|
| Concept/Terms |
11-beta-Hydroxysteroid Dehydrogenase Type 2- 11-beta-Hydroxysteroid Dehydrogenase Type 2
- 11 beta Hydroxysteroid Dehydrogenase Type 2
- 11beta-Hydroxysteroid Dehydrogenase Type 2
- 11beta Hydroxysteroid Dehydrogenase Type 2
- 11beta-HSD2
- 11beta-HSD2 Reductase
- 11 beta-HSD2
- 11 beta-Hydroxysteroid Dehydrogenase Type 2
|
Below are MeSH descriptors whose meaning is more general than "11-beta-Hydroxysteroid Dehydrogenase Type 2".
Below are MeSH descriptors whose meaning is more specific than "11-beta-Hydroxysteroid Dehydrogenase Type 2".
This graph shows the total number of publications written about "11-beta-Hydroxysteroid Dehydrogenase Type 2" by people in this website by year, and whether "11-beta-Hydroxysteroid Dehydrogenase Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "11-beta-Hydroxysteroid Dehydrogenase Type 2" by people in Profiles.
-
Wieczorek A, Perani CV, Nixon M, Constancia M, Sandovici I, Zazara DE, Leone G, Zhang MZ, Arck PC, Solano ME. Sex-specific regulation of stress-induced fetal glucocorticoid surge by the mouse placenta. Am J Physiol Endocrinol Metab. 2019 07 01; 317(1):E109-E120.
-
Yau M, Haider S, Khattab A, Ling C, Mathew M, Zaidi S, Bloch M, Patel M, Ewert S, Abdullah W, Toygar A, Mudryi V, Al Badi M, Alzubdi M, Wilson RC, Al Azkawi HS, Ozdemir HN, Abu-Amer W, Hertecant J, Razzaghy-Azar M, Funder JW, Al Senani A, Sun L, Kim SM, Yuen T, Zaidi M, New MI. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11ß-hydroxysteroid dehydrogenase type 2 deficiency. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):E11248-E11256.
-
Yau M, Azkawi HS, Haider S, Khattab A, Badi MA, Abdullah W, Senani AA, Wilson RC, Yuen T, Zaidi M, New MI. A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred. Ann N Y Acad Sci. 2016 07; 1376(1):65-71.
-
Lin-Su K, Zhou P, Arora N, Betensky BP, New MI, Wilson RC. In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 2004 May; 89(5):2024-7.
-
Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoid excess. Trends Endocrinol Metab. 2001 Apr; 12(3):104-11.